

REMARKS


Enclosed herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a Substitute Sequence Listing to be inserted into the specification as indicated above. The Substitute Sequence Listing in no way introduces new matter into the specification. Also submitted herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a disk copy of the Substitute Sequence Listing. The disk copy of the Sequence Listing, file “2005-06-20 2121-0183PUS1.ST25.txt”, is identical to the paper copy, except that it lacks formatting.

The specification is amended to reference each nucleotide and amino acid sequence with a corresponding SEQ ID NO. The Sequence Listing is amended to identify the present application by filing date and serial number. SEQ ID NOS: 14 and 16 are amended to include residues which were inadvertently left out at the time of filing. Support for the amendments to SEQ ID NOS: 14 and 16 is found from the CD2 sequence shown in Figure 5. The Sequence Listing is further amended to include SEQ ID NOS: 18-103. These sequences can be found in the specification and figures as originally filed. No new matter is introduced by these amendments.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
MaryAnne Armstrong Reg. No.: 40,069

MAA/psq
2121-0183PUS1

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachments:

Disk Copy of Sequence Listing
Paper Copy of Sequence Listing
Copy of Notice to Comply